HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.

AbstractBACKGROUND:
Inhibitors of tyrosine kinases downstream of the B-cell receptor, such as Bruton's tyrosine kinase (Btk) or Spleen tyrosine kinase (Syk), used alone or in combination are new therapeutic options in the treatment of B-cell malignancies. A challenge in the development of second-generation Btk inhibitors is to limit their side effects such as the increased bleeding risk. Considering the pivotal role of Syk in immunoreceptor tyrosine-based activation motif mediated platelet signaling, the impact of inhibiting this kinase on platelet functions is also worth analyzing.
OBJECTIVES:
We investigated the effect of a novel Btk inhibitor, tirabrutinib, and a Syk inhibitor, entospletinib, alone and in combination on platelet signaling and functions in vitro and ex vivo.
METHODS:
Platelet aggregation, secretion, and signaling responses as well as thrombus growth under flow were analyzed in the presence of the inhibitors alone or in combination in vitro, at clinically relevant doses, and ex vivo in patients treated with these inhibitors in the context of a phase I trial.
RESULTS:
Although tirabrutinib alone had modest effects on platelet activation in vitro and ex vivo, entospletinib alone efficiently inhibited washed platelet aggregation in response to collagen. However, entospletinib weakly affected platelet activation in platelet-rich plasma, in whole blood and ex vivo. Importantly, the combination of tirabrutinib and entospletinib induced a significant decrease in platelet response to collagen in vitro and ex vivo correlating with mild bleedings reported in some of the treated patients.
CONCLUSION:
These new results should contribute to improve the safety of these targeted therapies.
AuthorsJennifer Series, Agnès Ribes, Cédric Garcia, Pierre Souleyreau, Anne Bauters, Franck Morschhauser, Juliane M Jürgensmeier, Pierre Sié, Loïc Ysebaert, Bernard Payrastre
JournalJournal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 18 Issue 12 Pg. 3336-3351 (12 2020) ISSN: 1538-7836 [Electronic] England
PMID32926549 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2020 International Society on Thrombosis and Haemostasis.
Chemical References
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • SYK protein, human
  • Syk Kinase
Topics
  • Agammaglobulinaemia Tyrosine Kinase
  • Hemostasis
  • Humans
  • Platelet Activation
  • Platelet Aggregation
  • Protein-Tyrosine Kinases
  • Syk Kinase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: